title: EGFR/HER-targeted therapeutics in ovarian cancer.
abstract: Despite decades of research and evolving treatment modalities, survival among patients with epithelial ovarian cancer has improved only incrementally. During this same period, the development of biologically targeted therapeutics has improved survival for patients with diverse malignancies. Many of these new drugs target the human epidermal growth factor receptor (EGFR/HER/ErbB) family of tyrosine kinases, which play a major role in the etiology and progression of many carcinomas, including epithelial ovarian cancer. While several HER-targeted therapeutics are US FDA approved for the treatment of various malignancies, none have gained approval for the treatment of ovarian cancer. Here, we review the published literature on HER-targeted therapeutics for the treatment of ovarian cancer, including novel HER-targeted therapeutics in various stages of clinical development, as well as the challenges that have limited the use of these inhibitors in clinical settings.
authors.affiliation: Yale University, Department of Obstetrics, Gynecology & Reproductive Sciences, New Haven, CT 06520, USA.
authors.forename: Jason A
authors.initials: JA
authors.lastname: Wilken
authors.forename: Tayf
authors.initials: T
authors.lastname: Badri
authors.forename: Sarah
authors.initials: S
authors.lastname: Cross
authors.forename: Rhoda
authors.initials: R
authors.lastname: Raji
authors.forename: Alessandro D
authors.initials: AD
authors.lastname: Santin
authors.forename: Peter
authors.initials: P
authors.lastname: Schwartz
authors.forename: Adam J
authors.initials: AJ
authors.lastname: Branscum
authors.forename: Andre T
authors.initials: AT
authors.lastname: Baron
authors.forename: Adam I
authors.initials: AI
authors.lastname: Sakhitab
authors.forename: Nita J
authors.initials: NJ
authors.lastname: Maihle
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000077216:Carcinoma, Ovarian Epithelial; D049109:Cell Proliferation / Q000187:drug effects; D002986:Clinical Trials as Topic; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000378:metabolism; D005260:Female; D006801:Humans; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000378:metabolism; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D066246:ErbB Receptors; D047428:Protein Kinase Inhibitors; D018719:Erb-b2 Receptor Tyrosine Kinases